Transcatheter aortic valve implantation (TAVI) provides a promising advancement in the management of aortic stenosis. Previous studies have identified the benefit of this technology, particularly in those at high risk for surgical intervention. Because of this well-documented success, TAVI was introduced to Dunedin Hospital in 2015. This study provides a retrospective observational audit of TAVI cases between 2015 and 2019 (n=71). TAVI cases were also compared against patients that had surgical aortic valve implantation (SAVI) between 2011 and 2016 (n=134) at Dunedin Hospital. Data were collected using the Heath Connect South (HCS) database, and the Society of Thoracic Surgeons (STS) and EuroSCORE surgical risk predictors calculated. It was found that TAVI patients were older, with higher surgical risk scores and greater comorbidities. Even so, rates of cardiovascular events and hospital readmissions were similar between the two groups over two years, and stroke more common in SAVI. These trends were most evident in the 80–89-year-olds. Thirty-day mortality was 4.2% for TAVI and 2.2% for SAVI. TAVI patients also spent significantly less time in hospital (2.4 days vs 9.3 days). These Results suggest the effective implementation of TAVI within Dunedin Hospital, with thirty-day mortality comparable to previous international studies. The 80-89-year-old cohort also received the greatest benefit from TAVI, which is precisely the group that has the most to gain from this procedure.